Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer

Ki vehet részt

• Diagnosis of stage I-IIIA NSCLC planned for surgical resection
• Eastern Cooperative Oncology Group (ECOG) 0-2 performance status
• Willingness and ability to undergo planned correlative studies, including imaging tests
• Fresh biopsy diagnostic material obtained from standard of care procedure to perform baseline correlatives (10-15 slides)-if not available, enrollment will be considered on a case-by-case basis after discussion with and approval by the Lead Site PI or Lead Site Co-Principal Investigator
• Ability to understand and the willingness to sign a written informed consent
• All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; 6a. A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:; • Has not undergone a hysterectomy or bilateral oophorectomy; or; • Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
• Age ≥22 years at time of screening

Ki nem vehet részt

• Receipt of prior therapy for the current NSCLC
• Planned neoadjuvant therapy for the current NSCLC
• History of major allergic reactions attributed to adhesive or compounds in TTFields micro-array
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements
• Pregnant or nursing patients due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants
• Use of electronic devices or prosthetics - i.e., pacemakers, defibrillators, spinal infusion pumps. Specific scenarios can be discussed with the Lead Site PI or Lead Site Co-Principal Investigator